scispace - formally typeset
A

Aleš Linhart

Researcher at First Faculty of Medicine, Charles University in Prague

Publications -  371
Citations -  36568

Aleš Linhart is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Fabry disease & Medicine. The author has an hindex of 50, co-authored 333 publications receiving 30467 citations. Previous affiliations of Aleš Linhart include University Hospital of Wales & Charles University in Prague.

Papers
More filters
Journal ArticleDOI

Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic.

TL;DR: SSc patients diagnosed withPAH through screening have less advanced disease in terms of haemodynamics than those with PAH diagnosed previously based on symptoms; their prognosis is therefore likely to be more favourable.
Journal ArticleDOI

Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative

TL;DR: The PREDICT-FD initiative captured global opinion regarding current clinical indicators that could prompt FD-specific treatment initiation earlier than is currently practised.
Journal ArticleDOI

Advances in accelerometry for cardiovascular patients: a systematic review with practical recommendations.

TL;DR: The methods used for collecting and processing accelerometer data in cardiology are reviewed, using the example of heart failure, to provide practical recommendations on how to improve objective physical activity assessment in patients with cardiovascular diseases by using accelerometers.
Journal ArticleDOI

Inflammatory response in patients undergoing hip surgery due to osteoarthrosis or different types of hip fractures.

TL;DR: In patients with hip fractures, inflammatory markers are elevated already preoperatively, more so in IC than in EC fractures, and there is a significant suppression of sP-selectin and sE- selectin values in all subgroups after surgery.
Journal ArticleDOI

Common presentation of rare diseases: Left ventricular hypertrophy and diastolic dysfunction

TL;DR: As there are specific therapies for some forms of HCM including enzyme substitution and chaperone therapies and specific treatments for TTR amyloidosis, a differential diagnosis should be sought in all patients with unexplained left ventricular hypertrophy.